Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .

Inclusion Criteria: * \- Healthy subjects aged 10-60 years as established by medical history and clinical examination * The subjects are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting Exclusion Criteria: * \- Subject who was administered human rabies vaccine. * Suspected or have a history of injury caused by warm-blooded mammals. * Women who are breastfeeding, pregnant, or planning to become pregnant during the trial. * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, especially allergic to neomycin. * Has been diagnosed or suspected of having an immune deficiency, autoimmune disease, or immune system disorder. * History of thyroidectomy, or thyroid disease requiring treatmentin the past 12 months * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with injections or blood draws * History of epilepsy, convulsions or convulsions, or a family history of psychosis. * Absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy. * Have a serious chronic illness (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders, guillain-barre syndrome) * Known or suspected co-existing diseases included: respiratory disease, acute infection or active period of chronic disease, HIV infection, cardiovascular disease, severe hypertension, malignant tumor treatment, skin disease. * In the past 6 months, there have been immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis). * Taking anti-TB prevention or treatment. * Any prior administration of blood products in last 3 months. * Any prior administration of other research drugs in last 30 days * Any prior administration of attenuated live vaccine in last 14 days * Any prior administration of subunit or inactivated vaccines in last 7 days * Had fever 3 days before vaccination, Subjects with temperature ≥38.0°C on axillary setting * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives